New number of shares and votes in BioInvent International AB (publ)
BioInvent International AB (publ) (OMXS: BINV) today announced that the company's total number of shares as per 30 June 2011 amounts to 67,205,257 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from an issue of 6,109,568 shares under BioInvent's directed new share issue that was announced on 1 June 2011.
-- END --
Notes to Editors:
About BioInvent
BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based
pharmaceutical company that focuses on developing antibody drugs. The Company currently has four clinical development projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances to strengthen the product pipeline and increase the likelihood of success. These partners include Genentech, Human Genome Sciences, Roche and ThromboGenics.
The company's competitive position is underpinned by an in substance patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe, UCB and XOMA. More information is available at www.bioinvent.com (http://www.bioinvent.com/).
For further information, please contact:
BioInvent International AB
Svein Mathisen                                                                       Â
President & CEOÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â
Tel: +46 (0)46-286 85 67Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â
Mobile: +46 (0)708-97 82 13Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â
E-mail: [email protected]Â ([email protected])Â Â Â Â Â Â Â Â Â Â Â Â
Sten Westerberg
Vice President, Investor Relations
Tel: +46 (0)46-286 85 52
Mobile: +46 (0)768-68 50 09
E-mail: [email protected]Â ([email protected])Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â ([email protected])
BioInvent International AB (publ)
Co. reg. No. 556537-7263,
Address: Sölvegatan 41
Mailing address: SE-223 70 LUND
Tel: +46 (0)46 286 85 50
[email protected]Â ([email protected])
www.bioinvent.com (http://www.bioinvent.com/)
Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.30 a.m. CET, on 30 June, 2011.